STOCK TITAN

Aurora Cannabis Inc. Common Shares - ACB STOCK NEWS

Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.

Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.

In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.

Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.

Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.

With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.

Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) has launched a new cannabis cultivar, Valour, specifically designed for veterans. This product, marketed under the MedReleaf brand, features genetics from Chemdawg, OG18, and Skunk, with THC levels ranging from 20-26%. Five percent of Valour's net profits will support veteran organizations across Canada, with a cap of $200,000 per year. Valour aims to meet veterans' needs by embodying their preferred traits in aroma and flavor. The initiative highlights Aurora's commitment to the veteran community and aims to foster significant contributions to organizations providing essential support to veterans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) and MedReleaf Australia have launched CraftPlant, a new medical cannabis brand for Australian patients. This brand features three THC-dominant strains—Greendae, Navana, and HiVolt—developed from premium cultivars by Aurora's science division, Occo. The products are produced under strict EU-GMP guidelines and are available in 10g containers. Aurora holds a 10% stake in MedReleaf Australia and aims to enhance its presence in the promising Australian market. The partnership increases the total MedReleaf products available for Australian doctors to 27, offering diverse treatment solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis (ACB) reported a Q2 2023 net revenue of $61.7 million, a 25% increase from Q1 2023, driven by growth across all cannabis segments and a full contribution from Bevo Agtech Inc. Additionally, the company achieved a positive Adjusted EBITDA of $1.4 million, marking a significant turnaround from previous losses. Aurora has realized approximately $340 million in annual cost savings since early 2020 and reduced debt by $302 million in 2022. Despite a net loss of $67.2 million, the company maintains a net cash position, with approximately $310 million in cash as of February 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Rhea-AI Summary

Aurora Cannabis Inc. (ACB) announced a conference call to discuss its second quarter financial results for fiscal year 2023, scheduled for February 9, 2023, at 5:00 p.m. ET. The financial results will be released after the market closes the same day. CEO Miguel Martin and CFO Glen Ibbott will host the call, which will also include a Q&A session. Investors can access the webcast through the company's investor info page. Aurora continues to serve both medical and consumer markets with a strong brand portfolio, emphasizing its commitment to high-quality cannabis products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences earnings
-
Rhea-AI Summary

Aurora Cannabis closed the sale of its Aurora Polaris facility, generating approximately $15 million in gross proceeds. This sale is part of the company's ongoing transformation strategy. Following this transaction, Aurora maintains a strong balance sheet with about $320 million in cash and cash equivalents, including $63 million of restricted cash. The company expects to achieve Adjusted EBITDA profitability for the quarter ending December 31, 2022, further solidifying its position in the cannabis industry as a leader in both medical and consumer markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
Rhea-AI Summary

Aurora Cannabis (ACB) announced the repurchase of approximately $102.5 million of its convertible senior notes for $99.4 million in cash, achieving a 4.5% discount. This marks a total repurchase of $316.5 million over the past year, leading to annual cash interest savings of $17.4 million. The company reports a strong balance sheet and aims to achieve Adjusted EBITDA profitability by December 31, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
buyback
-
Rhea-AI Summary

Aurora Cannabis Inc. (ACB) announced the results of its Annual General and Special Meeting held on November 14, 2022. A total of 92,937,078 shares, or 30.93% of issued shares, were represented. All proposed matters were approved, including the election of directors with high approval rates: Miguel Martin received 92.56% support, and Norma Beauchamp 83.50%. Shareholders also approved KPMG as auditors and amendments to several compensation plans. The voting results report is available on SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) will discuss its Q1 fiscal year 2023 results on November 10, 2022, at 5:00 p.m. ET. The Company will announce its financial results after market close on the same day. Aurora continues to carve a niche in the cannabis industry, emphasizing quality and innovation in both medical and consumer markets. The conference call will feature CEO Miguel Martin and CFO Glen Ibbott, providing insights into the Company's financial performance and future outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
conferences earnings
Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB, TSX: ACB) has filed its management information circular in preparation for its annual and special meeting of shareholders on November 14, 2022. The materials, now being mailed to shareholders, outline the business to be discussed, voting instructions, and participation details. Key items for voting include the election of nine directors, the appointment of KPMG LLP as auditors, and amendments to the stock option plan. The Board recommends voting in favor of all proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none

FAQ

What is the current stock price of Aurora Cannabis Common Shares (ACB)?

The current stock price of Aurora Cannabis Common Shares (ACB) is $4.27 as of December 20, 2024.

What is the market cap of Aurora Cannabis Common Shares (ACB)?

The market cap of Aurora Cannabis Common Shares (ACB) is approximately 225.0M.

What is Aurora Cannabis Inc. primarily known for?

Aurora Cannabis Inc. is known for the cultivation, production, and sale of high-quality cannabis products for both medical and recreational use.

Where is Aurora Cannabis Inc. headquartered?

Aurora Cannabis Inc. is headquartered in Edmonton, Alberta, Canada.

What are some of the brands under Aurora Cannabis?

Some of the brands under Aurora Cannabis include Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard.

What recent products has Aurora Cannabis launched?

Aurora Cannabis recently launched three new cannabis-infused beverages and resin cartridges in Australia, catering to patient needs with innovative and high-quality products.

What is Aurora's financial outlook for 2024?

Aurora expects to achieve positive free cash flow in calendar 2024 and has recently completed the repayment of nearly $465 million in convertible debt.

What significant acquisitions has Aurora made recently?

Aurora acquired the remaining equity interest in MedReleaf Australia, strengthening its position in the Australian medical cannabis market.

What certifications do Aurora's production facilities hold?

Aurora's production facilities hold EU-GMP and TGA-GMP certifications, ensuring compliance with rigorous international quality standards.

How does Aurora contribute to the U.S. cannabis market?

Aurora's wholly-owned subsidiary, Australis Capital Inc., actively participates in the U.S. cannabis market.

What international operations does Aurora have?

Aurora has expanded internationally through medical cannabis exporting agreements, with a significant presence in Europe and Australia.

How does Aurora ensure the quality of its products?

Aurora ensures the quality of its products through advanced cultivation techniques and compliance with international standards like EU-GMP and TGA-GMP.

Aurora Cannabis Inc. Common Shares

Nasdaq:ACB

ACB Rankings

ACB Stock Data

225.00M
54.75M
13.04%
7.99%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Edmonton